<rst>
<header>
	<relations>
			<rel name="elaboration" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="purpose" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="same_unit" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">1. Introduction</segment>
<segment id="2" parent="1001" relname="joint">Primary liver cancer is the sixth most prevalent cancer and the second leading cause of cancer mortality worldwide .</segment>
<segment id="3" parent="1004" relname="span">The most common primary liver cancer is hepatocellular carcinoma</segment>
<segment id="4" parent="3" relname="restatement">( HCC ) ,</segment>
<segment id="5" parent="1003" relname="same_unit">which accounts for &gt;85 % of all cases .</segment>
<segment id="6" parent="1006" relname="span">HCC predominantly arises in the setting of cirrhosis</segment>
<segment id="7" parent="6" relname="elaboration">associated with hepatitis B and C virus infections , alcohol abuse , non-alcoholic steatohepatitis and metabolic diseases .</segment>
<segment id="8" parent="1001" relname="joint">Early-stage HCC patients are often subjected to surgical resection and liver transplantation .</segment>
<segment id="9" parent="1009" relname="joint">However , 5-year recurrence rates after resection reach &gt;70 %</segment>
<segment id="10" parent="1009" relname="joint">and the efficiency of transplantation is limited by organ shortage and technical issues .</segment>
<segment id="11" parent="12" relname="concession">Although local ablation and transarterial chemoembolization respectively confer 5-year survival rates of 50 â€“ 70 % and survival benefit of &gt;6 months ,</segment>
<segment id="12" parent="1011" relname="span">they are confined to patients with single tumors or multinodular tumors with good liver reserve .</segment>
<segment id="13" parent="1014" relname="span">Chemotherapy is not routinely used</segment>
<segment id="14" parent="13" relname="elaboration">due to the chemoresistant character of HCC .</segment>
<segment id="15" parent="1017" relname="span">For advanced HCC , sorafenib , a multi-tyrosine kinase inhibitor</segment>
<segment id="16" parent="15" relname="elaboration">( MTKI ) ,</segment>
<segment id="17" parent="1016" relname="same_unit">has been the only approved systemic first-line agent for over a decade ,</segment>
<segment id="18" parent="1016" relname="circumstance">until lenvatinib , another MTKI , recently came into play .</segment>
<segment id="19" parent="1019" relname="preparation">Yet , their clinical efficacy was suboptimal ,</segment>
<segment id="20" parent="1020" relname="span">with only ~3 months of prolonged survival .</segment>
<segment id="21" parent="1021" relname="joint">Second-line treatments include regorafenib and cabozantinib , also MTKIs ;</segment>
<segment id="22" parent="1022" relname="span">nivolumab and pembrolizumab , immune checkpoint inhibitors</segment>
<segment id="23" parent="1024" relname="span">targeting programmed death-1</segment>
<segment id="24" parent="23" relname="restatement">( PD-1 ) ;</segment>
<segment id="25" parent="1026" relname="span">and ramucirumab , the first biomarker-driven therapeutics</segment>
<segment id="26" parent="1027" relname="span">approved for HCC</segment>
<segment id="27" parent="1028" relname="span">that targets the angiogenic vascular endothelial growth factor receptor</segment>
<segment id="28" parent="27" relname="elaboration">( VEGFR ) ,</segment>
<segment id="29" parent="1029" relname="span">all of which have not been established</segment>
<segment id="30" parent="1030" relname="joint">until the past few years</segment>
<segment id="31" parent="1030" relname="joint">and require further investigations .</segment>
<segment id="32" parent="1032" relname="same_unit">So far , treatment outcomes for HCC are far from satisfactory ,</segment>
<segment id="33" parent="1032" relname="same_unit">with a 5-year survival rate of only ~18 % .</segment>
<segment id="34" parent="1034" relname="span">Evidently , there is an urgent need</segment>
<segment id="35" parent="34" relname="purpose">to develop more effective therapeutic strategies in HCC .</segment>
<segment id="36" parent="1037" relname="span">Signal transducer and activator of transcription 3</segment>
<segment id="37" parent="36" relname="elaboration">( STAT3 )</segment>
<segment id="38" parent="1038" relname="span">has recently emerged as a potential therapeutic target for HCC</segment>
<segment id="39" parent="38" relname="elaboration">due to its crucial roles in oncogenesis .</segment>
<segment id="40" parent="1041" relname="span">STAT3 was initially determined to control acute-phase genes in response to interleukin-6</segment>
<segment id="41" parent="40" relname="restatement">( IL-6 )</segment>
<segment id="42" parent="1043" relname="span">and epidermal growth factor</segment>
<segment id="43" parent="42" relname="restatement">( EGF )</segment>
<segment id="44" parent="1042" relname="same_unit">during inflammation .</segment>
<segment id="45" parent="1045" relname="span">It belongs to the STAT family of cytoplasmic transcription factors</segment>
<segment id="46" parent="45" relname="elaboration">that mediate signal transduction from the plasma membrane to the nucleus in various cellular activities .</segment>
<segment id="47" parent="1047" relname="span">The STAT family comprises seven members :</segment>
<segment id="48" parent="47" relname="elaboration">STAT1 , 2 , 3 , 4 , 5a , 5b and 6 .</segment>
<segment id="49" parent="1050" relname="span">Each of them consists of</segment>
<segment id="50" parent="49" relname="restatement">( i )</segment>
<segment id="51" parent="1052" relname="span">an N-terminal domain for oligomerization ,</segment>
<segment id="52" parent="51" relname="restatement">( ii )</segment>
<segment id="53" parent="1054" relname="span">a coiled-coil domain for interaction with regulatory proteins ,</segment>
<segment id="54" parent="53" relname="restatement">( iii )</segment>
<segment id="55" parent="1056" relname="span">a DNA-binding domain for recognition of specific DNA sequences ,</segment>
<segment id="56" parent="55" relname="restatement">( iv )</segment>
<segment id="57" parent="1058" relname="span">a Src homology-2</segment>
<segment id="58" parent="57" relname="elaboration">( SH2 )</segment>
<segment id="59" parent="1060" relname="span">domain</segment>
<segment id="60" parent="59" relname="elaboration">that triggers phosphorylation and dimerization</segment>
<segment id="61" parent="1061" relname="joint">after docking to phosphorylated receptors</segment>
<segment id="62" parent="1063" relname="span">and</segment>
<segment id="63" parent="62" relname="restatement">( iv )</segment>
<segment id="64" parent="1067" relname="span">a C-terminal transactivation domain with specific tyrosine</segment>
<segment id="65" parent="64" relname="restatement">( Y )</segment>
<segment id="66" parent="1067" relname="restatement">( present in all STATs )</segment>
<segment id="67" parent="1068" relname="span">and serine</segment>
<segment id="68" parent="67" relname="restatement">( S )</segment>
<segment id="69" parent="1070" relname="span">residues</segment>
<segment id="70" parent="69" relname="elaboration">( absent in STAT2 and 6 )</segment>
<segment id="71" parent="1070" relname="elaboration">that are phosphorylated upon transcriptional activation .</segment>
<segment id="72" parent="1072" relname="span">Intensive investigation has been done on STAT3 since its discovery ,</segment>
<segment id="73" parent="72" relname="elaboration">revealing its physiological roles in early embryonic development , growth and differentiation of various adult tissues .</segment>
<segment id="74" parent="1073" relname="span">In addition , its pathogenic roles in cancer initiation , progression , metastasis , chemoresistance and immunoevasion have been uncovered .</segment>
<segment id="75" parent="1074" relname="joint">To date , STAT3 is widely recognized as an oncogenic factor in diverse human cancers .</segment>
<segment id="76" parent="77" relname="background">Therefore , targeting STAT3 might be an attractive therapeutic strategy for HCC treatment .</segment>
<segment id="77" parent="1075" relname="span">In this review , we summarize the oncogenic roles of STAT3 in HCC and the current clinical development of STAT3-targeted therapeutics .</segment>
<group id="1000" type="span" />
<group id="1001" type="multinuc" parent="1000" relname="span"/>
<group id="1003" type="multinuc" parent="1001" relname="joint"/>
<group id="1004" type="span" parent="1003" relname="same_unit"/>
<group id="1006" type="span" parent="1001" relname="joint"/>
<group id="1008" type="span" parent="1001" relname="joint"/>
<group id="1009" type="multinuc" parent="1008" relname="span"/>
<group id="1010" type="span" parent="1009" relname="concession"/>
<group id="1011" type="span" parent="1012" relname="preparation"/>
<group id="1012" type="multinuc" parent="1010" relname="span"/>
<group id="1013" type="span" parent="1012" relname="joint"/>
<group id="1014" type="span" parent="1013" relname="span"/>
<group id="1015" type="span" parent="1014" relname="elaboration"/>
<group id="1016" type="multinuc" parent="1015" relname="span"/>
<group id="1017" type="span" parent="1016" relname="same_unit"/>
<group id="1018" type="span" parent="1012" relname="joint"/>
<group id="1019" type="multinuc" parent="1018" relname="span"/>
<group id="1020" type="span" parent="1019" relname="joint"/>
<group id="1021" type="multinuc" parent="20" relname="elaboration"/>
<group id="1022" type="span" parent="1021" relname="joint"/>
<group id="1023" type="multinuc" parent="22" relname="elaboration"/>
<group id="1024" type="span" parent="1023" relname="joint"/>
<group id="1025" type="multinuc" parent="1023" relname="joint"/>
<group id="1026" type="span" parent="1025" relname="same_unit"/>
<group id="1027" type="span" parent="25" relname="elaboration"/>
<group id="1028" type="span" parent="26" relname="elaboration"/>
<group id="1029" type="span" parent="1025" relname="same_unit"/>
<group id="1030" type="multinuc" parent="29" relname="circumstance"/>
<group id="1031" type="multinuc" parent="1019" relname="joint"/>
<group id="1032" type="multinuc" parent="1031" relname="joint"/>
<group id="1033" type="multinuc" parent="1031" relname="joint"/>
<group id="1034" type="span" parent="1033" relname="joint"/>
<group id="1035" type="multinuc" parent="1033" relname="joint"/>
<group id="1036" type="multinuc" parent="1035" relname="joint"/>
<group id="1037" type="span" parent="1036" relname="same_unit"/>
<group id="1038" type="span" parent="1036" relname="same_unit"/>
<group id="1039" type="multinuc" parent="1035" relname="joint"/>
<group id="1040" type="multinuc" parent="1039" relname="joint"/>
<group id="1041" type="span" parent="1040" relname="same_unit"/>
<group id="1042" type="multinuc" parent="1040" relname="same_unit"/>
<group id="1043" type="span" parent="1042" relname="same_unit"/>
<group id="1044" type="multinuc" parent="1039" relname="joint"/>
<group id="1045" type="span" parent="1044" relname="joint"/>
<group id="1046" type="multinuc" parent="1044" relname="joint"/>
<group id="1047" type="span" parent="1046" relname="joint"/>
<group id="1048" type="multinuc" parent="1046" relname="joint"/>
<group id="1049" type="multinuc" parent="1048" relname="joint"/>
<group id="1050" type="span" parent="1049" relname="same_unit"/>
<group id="1051" type="multinuc" parent="1049" relname="same_unit"/>
<group id="1052" type="span" parent="1051" relname="same_unit"/>
<group id="1053" type="multinuc" parent="1051" relname="same_unit"/>
<group id="1054" type="span" parent="1053" relname="same_unit"/>
<group id="1055" type="multinuc" parent="1053" relname="same_unit"/>
<group id="1056" type="span" parent="1055" relname="same_unit"/>
<group id="1057" type="multinuc" parent="1055" relname="same_unit"/>
<group id="1058" type="span" parent="1057" relname="same_unit"/>
<group id="1059" type="span" parent="1057" relname="same_unit"/>
<group id="1060" type="span" parent="1059" relname="span"/>
<group id="1061" type="multinuc" parent="1060" relname="circumstance"/>
<group id="1062" type="multinuc" parent="1061" relname="joint"/>
<group id="1063" type="span" parent="1062" relname="same_unit"/>
<group id="1064" type="multinuc" parent="1062" relname="same_unit"/>
<group id="1065" type="multinuc" parent="1064" relname="same_unit"/>
<group id="1066" type="span" parent="1065" relname="joint"/>
<group id="1067" type="span" parent="1066" relname="span"/>
<group id="1068" type="span" parent="1065" relname="joint"/>
<group id="1069" type="span" parent="1064" relname="same_unit"/>
<group id="1070" type="span" parent="1069" relname="span"/>
<group id="1071" type="multinuc" parent="1048" relname="joint"/>
<group id="1072" type="span" parent="1071" relname="joint"/>
<group id="1073" type="span" parent="1071" relname="joint"/>
<group id="1074" type="multinuc" parent="74" relname="purpose"/>
<group id="1075" type="span" parent="1074" relname="joint"/>
	</body>
</rst>
